Genomic predictors of response to doxorubicin versus docetaxel in breast cancer
Source: NCBI BioProject (ID PRJNA127219)
Source: NCBI BioProject (ID PRJNA127219)
0 0
Project name: Homo sapiens
Description: Low topo2a expression and ER-negative status were predictors of response to doxorubicin, while small tumor size and ER-negative status predicted response to docetaxel. Docetaxel was superior to doxorubicin in triple-negative/basal-like tumors, while no significant differences between these drugs were seen in the remaining intrinsic subtypesKeywords: reference x sampleOverall design: reference x sample
Data type: Transcriptome or Gene expression
Sample scope: Multiisolate
Relevance: Medical
Organization: Professor of Genetics, and Pathology & Laboratory Medicine; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Release date: 2011-05-27
Last updated: 2010-05-25